IRCT20201024049134N4尚未招募2 期
The Efficacy of standard treatment and dimethyl fumarate in the treatment of patients with COVID-19
试验速览
- 阶段
- 2 期
- 状态
- 尚未招募
- 入组人数
- 30
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 18 years 至 no limit（—）
- 性别
- All
入选标准
- •Men and women of at least 18 years of age capable of providing informed consent
- •Confirmation of COVID-19 with RT-PCR
- •Need for hospitalization
- •No need for mechanical ventilation
- •No need to more than 10 L/min of supplemental oxygen by any device.
- •The patient must meet at least one of the following high-risk criteria: age 70 years or older, obesity (BMI = 30 kg/m2), diabetes mellitus, uncontrolled blood pressure (systolic blood pressure> 150 mm Hg), history of respiratory disease (Including asthma or COPD), history of heart failure, history of coronary artery disease, fever > 38.4°C in the last 48 hours, shortness of breath at the time of referral, Bicytopenia, Pancytopenia, or a combination of neutrophilia and lymphopenia
排除标准
- •History of allergy to dimethyl fumarate
- •Use of dimethyl fumarate before current hospitalization
- •Patients more than 70 years of age with a history of any of the following in the last six months: Class III / IV Heart Failure Based on the New York Heart Association (NYHA) classification, Insulin-dependent diabetes, Angina pectoris, Malignancy
- •Uncontrolled bacterial, fungal, or viral infection (other than COVID-19).
- •Any history of receiving convalescent plasma therapy
- •Absolute neutrophil count (ANC) < 500
- •Platelets count < 50,000
- •Pregnant women or those intending to become pregnant
- •Breastfeeding women
- •AST or ALT > 5 times the upper limits of normal (ULN)
- •Estimated glomerular filtration rate (eGFR) < 30 ml/min in 1.73 m2 using MDRD equation
研究者
相似试验
进行中（未招募）
1 期
Dimethylfumarate for the treatment of Palmoplantar PustulosisPalmoplantar PustulosisMedDRA version: 20.0Level: LLTClassification code 10050185Term: Palmoplantar pustulosisSystem Organ Class: 100000004858EUCTR2017-003386-10-ATMedical University of Vienna25
尚未招募
不适用
In-vivo Bioequivalence Test of Dimethyl fumarate Capsules with brand drug (TECFIDERA® 240 mg, Biogen, Germany)Bioequivalence Study.IRCT20200105046010N43ABIDI Pharmaceutical Company24
尚未招募
不适用
Study of absorption and elimination rate of Dimethyl Fumarate 240-mg capsule in comparison with Dimethyl Fumarate brand Capsule (Tecfidera®).Bioequivalence study.IRCT20200407046981N27Avicenna Pharmaceutical Company24
招募中
3 期
Efficacy of dimethyl fumarate administration vs placebo on neurosurgical brain induced injury measured by S100 beta protein concentration and performance (Karnofsky scale) among glioblastoma multiform patientGliobalstom multiforme.Malignant neoplasm of brain, unspecifiedC71.9IRCT20200226046624N1Tehran University of Medical Sciences72
招募中
1 期
Effect of dimethyl fumarate administered to patients with adrenomyeloneuropathy: a multicenter, placebo controlled, phase IIb/III trialAdrenomyeloneuropathyCTIS2023-506795-27-00Fundacio Institut D Investigacio Biomedica De Bellvitge IDIBE40